Article in Metabolites, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors.
María Alejandrina Martínez-GonzálezUnidad de Investigación Médica Yucatán, Unidad Médica de Alta Especialidad, Hospital de Especialidades 1, Instituto Mexicano del Seguro Social, Merida 97150, Yucatan, Mexico.
Luis Manuel Peña-RodríguezUnidad de Biotecnología, Centro de Investigación Científica de Yucatán, A.C., Merida 97205, Yucatan, Mexico.ORCID 0000-0001-6511-5122
Andrés Humberto Uc-CachónUnidad de Investigación Médica Yucatán, Unidad Médica de Alta Especialidad, Hospital de Especialidades 1, Instituto Mexicano del Seguro Social, Merida 97150, Yucatan, Mexico.ORCID 0000-0003-3845-7930
Jorge BórquezDepartamento de Química, Facultad de Ciencias Básicas, Universidad de Antofagasta, Antofagasta 02800, Chile.ORCID 0000-0003-1803-9272
Mario J SimirgiotisDepartamento de Química, Facultad de Ciencias Básicas, Universidad de Antofagasta, Antofagasta 02800, Chile.ORCID 0000-0003-4552-3123
Hugo Brígido Barrios-GarcíaFacultad de Medicina Veterinaria y Zootecnia, Universidad Autónoma de Tamaulipas, Ciudad Victoria 87000, Tamaulipas, Mexico.ORCID 0000-0001-7590-319X
Rogelio Hernández-PandoDepartamento de Patología Experimental, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), Ciudad de Mexico 14080, Mexico.
Luis Alberto LoyolaDepartamento de Química, Facultad de Ciencias Básicas, Universidad de Antofagasta, Antofagasta 02800, Chile.
Carlos ArecheDepartamento de Química, Facultad de Ciencias, Universidad de Chile, Santiago 1058, Chile.ORCID 0000-0001-5246-1368
Angel de Jesús Dzul-BehUnidad de Investigación Médica Yucatán, Unidad Médica de Alta Especialidad, Hospital de Especialidades 1, Instituto Mexicano del Seguro Social, Merida 97150, Yucatan, Mexico.ORCID 0000-0002-4971-7833
Jorge Alberto Barrios-PayánDepartamento de Patología Experimental, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), Ciudad de Mexico 14080, Mexico.
Dulce Mata-EspinosaDepartamento de Patología Experimental, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), Ciudad de Mexico 14080, Mexico.
Fabiola Escalante-ErosaUnidad de Biotecnología, Centro de Investigación Científica de Yucatán, A.C., Merida 97205, Yucatan, Mexico.
Karlina García-SosaUnidad de Biotecnología, Centro de Investigación Científica de Yucatán, A.C., Merida 97205, Yucatan, Mexico.
Gloria María Molina-SalinasUnidad de Investigación Médica Yucatán, Unidad Médica de Alta Especialidad, Hospital de Especialidades 1, Instituto Mexicano del Seguro Social, Merida 97150, Yucatan, Mexico.ORCID 0000-0002-3961-6449
Funding
CONACYT-México fellowships 291061 and 22545CONACYT-México PDCPN2013/213558Instituto Mexicano del Seguro Social, Coordinación de Investigación en Salud Programa de Cooperación Internacional 2015 and 2017Universidad de Antofagasta Centro de Costos de Rectoría number 1001
6 · The paper itself
Abstract
Tuberculosis causes more than 1.2 million deaths each year. Worldwide, it is the first cause of death by a single infectious agent. The emergence of drug-resistant strains has limited pharmacological treatment of the disease and today, new drugs are urgently needed. Semi-synthetic mulinanes have previously shown important activity against multidrug-resistant (MDR)
Indexed as
MDRmulinanesMycobacterium tuberculosispre-XDR and XDR tuberculosissemi-synthetic derivatives
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Activity of Semi-Synthetic Mulinanes against MDR, Pre-XDR, and XDR Strains of · full record | OpenQuestion